The effect of metformin on clinical features of women with polycystic ovary syndrome

Introduction: Insulin resistance (IR) is one of the main features of polycystic ovary syndrome (PCOS), and metformin is one of the most commonly prescribed insulin sensitizers in its treatment. Research carried out so far shows heterogeneous results on the effects of metformin on the hormonal and metabolic status of women with PCOS. The aim of the study was to investigate the effect of six-month treatment with metformin (2000 mg per day) on the hormonal and metabolic characteristics of women with PCOS, paired with healthy women by body mass index (BMI) and age. Material and Methods: A number of 20 women with PCOS [age: 23.5 ± 5.9 years, BMI: 24.8 ± 4.2kg / m2] and 20 healthy control group women were tested (age: 24.5 ± 5.3 years, BMI: 23.6 ± 3.0kg / m2). Polycystic ovary syndrome was diagnosed with ESHRE / ASRM criteria. Standard biochemical and hormonal parameters were determined, which were repeated in the PCOS group and after six months of metformin therapy. Insulin resistance was determined using a homeostatic model (HOMA-IR). Results: After six months of metformin therapy in the PCOS group, there was a significant increase in the frequency of menstrual cycle (65% versus 87%, p